"Onasseio" Cardiosurgery Hospital, Hemodynamic Research and Interventional Cardiology Dept., 356, Syggrou Avenue
Welcome,         Profile    Billing    Logout  
 0 Trials 
3 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Voudris, Vassilios
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Checkmark [VIRTUAL] Advance Outcomes - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in Subjects with Pulmonary Arterial Hypertension
Checkmark Advance Outcomes - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in Subjects with Pulmonary Arterial Hypertension
Checkmark Study Design of the Phase 3 ADVANCE Program Evaluating Time-to-Clinical Events and Exercise Capacity in Patients with Pulmonary Arterial Hypertension Treated with Ralinepag
Recruiting
3
700
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/22
12/22
NCT04517955: TAVI in Intermediate Risk Septuagenarians With Risk Factors Not Captured by the Traditional Surgical Risk Scores

Recruiting
N/A
80
Europe
Transcatheter Aortic Valve Implantation (TAVI), Transcatheter Aortic Valve Replacement (TAVR)
University of Athens
Transcatheter Aortic Valve Replacement
09/22
03/25
Karyofyllis, Panagiotis
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Checkmark [VIRTUAL] Advance Outcomes - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in Subjects with Pulmonary Arterial Hypertension
Checkmark Advance Outcomes - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in Subjects with Pulmonary Arterial Hypertension
Checkmark Study Design of the Phase 3 ADVANCE Program Evaluating Time-to-Clinical Events and Exercise Capacity in Patients with Pulmonary Arterial Hypertension Treated with Ralinepag
Recruiting
3
700
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/22
12/22

Download Options